It has come as small comfort for
pulmonary clinicians that the two most prevalent obstructive lung diseases,
COPD and asthma, are being characterized as phenotypically heterogeneous. While it sheds light on the challenging
clinical management of patients with these diagnoses, it dredges up more
concerns about how exactly this variability in presentation should and could be
addressed to mitigate the disease-related impairment.
This month’s Clinical Review from Carolan
and Sutherland [Journal of Allergy & Clinical Immunology 2013; 131(3): 627-634] compiles important advances in understanding COPD
phenotypes, current knowledge of asthma phenotypes, where they overlap and the
focus of therapies. The authors cover
guidelines, clinical phenotypes, exacerbations and morbidity in both
diseases. They also discuss radiologic
phenotypes in COPD and the promising predictive tool, the BODE index, which
applies BMI, obstruction, dypsnea, and exercise capacity to predict disease
progression with greater accuracy than decline in FEV1.
Carolan and Sutherland note that COPD,
unlike asthma, has not yet been sensitively correlated to any inflammatory
biomarker, which has impaired programs for targeted drug development in COPD. Phenotypic cluster analyses for both diseases
are also covered in the authors’ review.
They comment that these efforts are creating alternative perspectives
that may be useful for improving management of the variable clinical
presentations. Improved characterization
of phenotype variability would permit development of personalized treatment
regimens for both COPD and asthma.